124 related articles for article (PubMed ID: 3801271)
21. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
Prezioso JA; FitzGerald GB; Wick MM
J Invest Dermatol; 1992 Sep; 99(3):289-93. PubMed ID: 1512464
[TBL] [Abstract][Full Text] [Related]
22. Cellular glutathione depletion by diethyl maleate or buthionine sulfoximine: no effect of glutathione depletion on the oxygen enhancement ratio.
Mitchell JB; Russo A; Biaglow JE; McPherson S
Radiat Res; 1983 Nov; 96(2):422-8. PubMed ID: 6647769
[TBL] [Abstract][Full Text] [Related]
23. Effect of DL-buthionine-S,R-sulfoximine on the growth of EMT6 and RIF mouse tumors.
Miller AC; Henderson BW
J Natl Cancer Inst; 1986 Aug; 77(2):505-10. PubMed ID: 3461211
[TBL] [Abstract][Full Text] [Related]
24. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
25. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
26. Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Gallo JM; Brennan J; Hamilton TC; Halbherr T; Laub PB; Ozols RF; O'Dwyer PJ
Cancer Res; 1995 Oct; 55(20):4507-11. PubMed ID: 7553617
[TBL] [Abstract][Full Text] [Related]
27. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
Kang YJ
Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
[TBL] [Abstract][Full Text] [Related]
28. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
Bier H
Laryngorhinootologie; 1990 Jan; 69(1):16-20. PubMed ID: 2310456
[TBL] [Abstract][Full Text] [Related]
29. SR-2508 plus buthionine sulfoximine or SR-2508 alone: effects on the radiation response and the glutathione content of a human tumor xenograft.
Lespinasse F; Biscay P; Malaise EP; Guichard M
Radiat Res; 1987 Apr; 110(1):149-54. PubMed ID: 2951766
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor.
Mayer RD; Lee KE; Cockett AT
Cancer Chemother Pharmacol; 1987; 20(3):207-10. PubMed ID: 2890443
[TBL] [Abstract][Full Text] [Related]
32. Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro.
Du DL; Volpe DA; Grieshaber CK; Murphy MJ
Cancer Res; 1990 Jul; 50(13):4038-43. PubMed ID: 2354454
[TBL] [Abstract][Full Text] [Related]
33. Spatial characterization of glutathione depletion in the KHT sarcoma using flow cytometry.
Minchinton AI; Chaplin DJ
Int J Radiat Biol; 1991 Jun; 59(6):1425-33. PubMed ID: 1677386
[TBL] [Abstract][Full Text] [Related]
34. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
Shrieve DC; Denekamp J; Minchinton AI
Radiat Res; 1985 Jun; 102(3):283-94. PubMed ID: 4070545
[TBL] [Abstract][Full Text] [Related]
35. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
36. Differential cytotoxicity of buthionine sulfoximine to "normal" and transformed human lung fibroblast cells.
Wan XS; St Clair DK
Cancer Chemother Pharmacol; 1993; 33(3):210-4. PubMed ID: 8269602
[TBL] [Abstract][Full Text] [Related]
37. Influence of buthionine sulfoximine and misonidazole on glutathione level and radiosensitivity of human tumor xenografts.
Guichard M; Lespinasse F; Malaise EP
Radiat Res; 1986 Jan; 105(1):115-25. PubMed ID: 3945723
[TBL] [Abstract][Full Text] [Related]
38. Buthionine sulfoximine pretreatment potentiates the effect of isolated lung perfusion with doxorubicin.
Port JL; Hochwald SN; Wang HY; Burt ME
Ann Thorac Surg; 1995 Aug; 60(2):239-43; discussion 244. PubMed ID: 7544099
[TBL] [Abstract][Full Text] [Related]
39. Effect of glutathione on sister-chromatid exchanges in normal and buthionine sulfoximine-treated mice.
Chatterjee A; Chattopadhyay A; Lawlor CJ
Mutat Res; 1995 Mar; 327(1-2):171-7. PubMed ID: 7870086
[TBL] [Abstract][Full Text] [Related]
40. Buthionine sulfoximine-induced cytostasis does not correlate with glutathione depletion.
Kang YJ; Enger MD
Am J Physiol; 1992 Jan; 262(1 Pt 1):C122-7. PubMed ID: 1733228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
